Phenotypical and potential functional characteristics of different immune cells expressing CD28H/B7-H5 and their relationship with cancer prognosis

Zhong, Chongli; Lang, Qi; Yu, Jie-Ping; Wu, Sheng; Xu, Feng; Tian, Yu

doi:10.1111/cei.13413

“…Moreover, CD103 and E-cadherin interaction play a vital role in granule polarization and exocytosis, enhancing recruitment and retention of tumor-antigen-specific TILs in human NSCLC. In human NSCLC, CD28H is mainly expressed in T RM cells and is thus associated with improved tumor prognosis ( 86 ). However, other studies conversely demonstrated opposite results that B7-H5 (the ligand of CD28H) was expressed in more than 60% of cases of NSCLC and was associated with worse prognosis.…”

Section: Lung T Rm Cells In Anti-tumor Immunitymentioning

confidence: 99%

The Roles of Tissue-Resident Memory T Cells in Lung Diseases

Yuan

¹

,

Yu

²

,

Jiao

³

et al. 2021

View full text Add to dashboard Cite

The unique environment of the lungs is protected by complex immune interactions. Human lung tissue-resident memory T cells (TRM) have been shown to position at the pathogen entry points and play an essential role in fighting against viral and bacterial pathogens at the frontline through direct mechanisms and also by orchestrating the adaptive immune system through crosstalk. Recent evidence suggests that TRM cells also play a vital part in slowing down carcinogenesis and preventing the spread of solid tumors. Less beneficially, lung TRM cells can promote pathologic inflammation, causing chronic airway inflammatory changes such as asthma and fibrosis. TRM cells from infiltrating recipient T cells may also mediate allograft immunopathology, hence lung damage in patients after lung transplantations. Several therapeutic strategies targeting TRM cells have been developed. This review will summarize recent advances in understanding the establishment and maintenance of TRM cells in the lung, describe their roles in different lung diseases, and discuss how the TRM cells may guide future immunotherapies targeting infectious diseases, cancers and pathologic immune responses.

show abstract

“…[ 14 ] In addition, HHLA2 is an inducer of the inflammatory response of antigen-presenting cells. [ 15 ] HHLA2 is widely expressed in a large proportion of tumor specimens, such as lung cancer, breast cancer, thyroid cancer, ovarian cancer, liver cancer, esophagus cancer, pancreatic cancer, bladder cancer, renal carcinoma, prostate cancer, and colon cancer. [ 16 ] Furthermore, recent studies have revealed that high HHLA2 protein expression in primary tumor tissues is associated with poor prognosis of cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of HHLA2 expression in solid tumors

Zhang

¹

,

Xu

²

,

Ye

³

et al. 2021

View full text Add to dashboard Cite

Background: Human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2), a newly discovered member of the B7 family, is overexpressed in numerous tumors. However, the prognostic impact of HHLA2 in human cancers remains controversial. Thus, we performed this meta-analysis to explore the prognostic value of HHLA2 in Chinese patients with solid tumors.Methods: PubMed, Embase, Web of Science, Chinese National Knowledge Infrastructure, and WanFang databases were systematically searched for eligible studies that evaluated the impact of HHLA2 on overall survival (OS) in patients with cancer. Hazard ratios (HRs) and 95% confidence intervals (CIs) were combined to evaluate the association between HHLA2 expression and OS in solid tumors. Odds ratios (ORs) and 95% CIs were pooled to assess the correlation between HHLA2 expression and clinicopathological characteristics in solid tumors.Results: A total of 12 studies, including 15 cohorts and 1747 patients, were included in this meta-analysis. We found that high HHLA2 expression was significantly associated with shorter OS (HR = 1.65, 95% CI: 1.12-2.43). Subgroup analysis by cancer type demonstrated that high HHLA2 expression was associated with poor OS in patients with clear cell renal cell carcinoma (HR = 3.42, 95% CI: 2.39-4.91), gastric cancer (HR = 2.03, 95% CI: 1.31-3.16), intrahepatic cholangiocarcinoma (HR = 1.77, 95% CI: 1.24-2.53), lung cancer (HR = 2.14, 95% CI: 1.33-3.44) and other cancer types (HR = 2.08, 95% CI: 1.34-3.24), but not in patients with epithelial ovarian cancer (HR = 0.52, 95% CI: 0.08-3.56). Nevertheless, high HHLA2 expression was associated with better OS in patients with pancreatic ductal adenocarcinoma (HR = 0.45, 95% CI: 0.32-0.64). Furthermore, high HHLA2 expression was associated with old age (OR = 1.30, 95% CI: 1.03-1.63), lymph node metastasis (OR = 1.99, 95% CI: 1.41-2.81), and vascular invasion (OR = 1.69, 95% CI: 1.18-2.42).Conclusions: HHLA2 may serve as a potential prognostic biomarker for solid tumors in Chinese population, by predict the prognosis of cancer patients based on their tumor types.Abbreviations: ccRCC = clear cell renal cell carcinoma, CIs = confidence intervals, CRC = colorectal cancer, CTLA-4 = cytotoxic T lymphocyte-associated antigen-4, EOC = epithelial ovarian cancer, GC = gastric cancer, HHLA2 = Human endogenous retrovirus-H long terminal repeat-associating protein 2, HR = Hazard ratio, ICC = intrahepatic cholangiocarcinoma, IHC = immunohistochemistey, IL = interleukin, LC = lung cancer, NOS = Newcastle-Ottawa Scale, ORs = odds ratios, OS = overall survival, OSCC = oral squamous cell carcinoma, PD-1 = programmed cell death protein 1, PDAC = pancreatic ductal adenocarcinoma,.

show abstract

“…Since there are few studies about sB7-H5 in AP, the mechanisms of sB7-H5 in AP are still unclear. According to the role of sB7-H5 in various cancers, it may have both coinhibitory functions in inhibiting the proliferation of human CD4 and CD8 T cells and the production of T cell cytokines or costimulatory functions in immune signalling [26]. In our study, the positive relationship between sB7-H5 and cytokines suggested a costimulatory function of sB7-H5 contributing to the progress of inflammation and severity in AP.…”

Section: Discussionmentioning

confidence: 48%

Soluble B7-H5 Is a Novel Diagnostic, Severity, and Prognosis Marker in Acute Pancreatitis

Xu¹,

Gong

²

,

Chen³

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

As an important ligand in T lymphocyte costimulatory pathways, B7-H5 is involved deeply in the immune response in various diseases. However, its clinical usefulness as an early indicator in acute pancreatitis (AP) remains unclear. In this study, the levels of sB7-H5 and cytokines in plasma samples of 75 AP patients, 20 abdominal pain patients without AP, and 20 healthy volunteers were determined. Then, the correlation of sB7-H5 and clinical features, cytokines, the Ranson score, APACHE II score, Marshall score, and BISAP score was analysed, and the value of sB7-H5 for diagnostic, severity, and prognosis of AP was evaluated. We found that the levels of sB7-H5 were specifically upregulated in AP patients. Receiver operating characteristic (ROC) analysis revealed that sB7-H5 can identify AP patients from healthy or abdominal pain patients with 78.9% or 86.4% sensitivity and 93.3% or 90.0% specificity. Further analysis showed that the levels of sB7-H5 were significantly correlated with WBC ( p = 0.004 ), GLU ( p = 0.008 ), LDH ( p < 0.001 ), Ca2+ ( p = 0.006 ), AST ( p = 0.009 ), PLT ( p = 0.041 ), IL-6 ( p < 0.001 ), IL-10 ( p < 0.001 ), and TNF-α ( p < 0.001 ). And levels of sB7-H5 were gradually increased among patients with mildly acute pancreatitis (MAP), moderately severe acute pancreatitis (MSAP), and severe acute pancreatitis (SAP). It can distinguish the severity of AP with good sensitivity and specificity. Moreover, when dividing the patients into two groups according to the median level of sB7-H5, the local complication and length of stay of low levels of the sB7-H5 group were significantly less than those in high levels of the sB7-H5 group. And the levels of sB7-H5 in AP patients were significantly correlated with the Ranson score ( p < 0.001 ), APACHE II score ( p < 0.001 ), Marshall score ( p < 0.001 ), and BISAP score ( p < 0.001 ). The AUCs of assessing local complications of sB7-H5 at day 1 and day 3 were 0.704 ( p = 0.0024 ) and 0.727 ( p = 0.0373 ). These results showed the potential value of sB7-H5 as a diagnostic, severity, and prognosis marker of AP.

show abstract

Phenotypical and potential functional characteristics of different immune cells expressing CD28H/B7-H5 and their relationship with cancer prognosis

Cited by 17 publications

References 70 publications

The Roles of Tissue-Resident Memory T Cells in Lung Diseases

The Roles of Tissue-Resident Memory T Cells in Lung Diseases

Prognostic value of HHLA2 expression in solid tumors

Soluble B7-H5 Is a Novel Diagnostic, Severity, and Prognosis Marker in Acute Pancreatitis

Contact Info

Product

Resources

About